Loading patent…
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsMichael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
Estimating the term…
The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
A method for reducing or lessening lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes in pigs infected with PCV2, said method comprising the step of administering a single dose of an immunogenic composition, said immunogenic composition comprising a polymer of acrylic or methacrylic acid and 4 μg to 400 μg of recombinant PCV2 ORF2 protein per single dose, wherein lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes are reduced or lessened in comparison to pigs not receiving said immunogenic composition.
Dependencies are inferred from the claim text.